Schedule Update - effective 1 March 2011 (text extract)

This is the text extract for Schedule Update - effective 1 March 2011, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 March 2011

Cumulative for January, February and March 2011 Section H cumulative for December 2010, January, February and March 2011

Contents

Summary of PHARMAC decisions effective 1 March 2011 ............................. 3 Pack size Changes – Champix and blood glucose test strips with lancets ...... 4 Gemcitabine hydrochloride – widening of access .......................................... 4 Pharmacy Brand Switch Payments ................................................................. 5 Cefaclor capsules – Tender News ................................................................... 5 Diabetes Nurse Prescribing ............................................................................ 6 Cerezyme – removal of Section 29 status ...................................................... 7 Klacid – new pack size ................................................................................... 7 Lanoxin PG – new pack size ........................................................................... 7 Tender News .................................................................................................. 8 Looking Forward ........................................................................................... 8 Sole Subsidised Supply products cumulative to March 2011....................... 10 New Listings ................................................................................................ 20 Changes to Restrictions ............................................................................... 24 Changes to Subsidy and Manufacturer’s Price............................................. 36 Changes to General Rules............................................................................ 38 Changes to Brand Name ............................................................................. 38 Changes to Sole Subsidised Supply ............................................................. 38 Delisted Items ............................................................................................. 39 Items to be Delisted .................................................................................... 44 Section H changes to Part II ........................................................................ 48 Index ........................................................................................................... 55

Summary of PharmaC decisions

effeCtIve 1 marCh 2011 New listings (page 20) • Lansoprazole (Lanzol Relief) cap 15 mg and 30 mg • Digoxin (Lanoxin PG) tab 62.5 μg – Up to 30 available on a PSO • Cefaclor monohydrate (Cefaclor Sandoz) cap 250 mg • Clarithromycin (Klacid) tab 250 mg – maximum of 500 mg per prescription; can be waived by Special Authority • Darunavir (Prezista) tab 600 mg – Special Authority – Retail pharmacy • Ritonavir (Norvir) tab 100 mg – Special Authority – Retail pharmacy • Ondansetron (Dr Reddy’s Ondansetron) tab disp 4 mg and 8 mg – maximum of 12 tab per prescription, maximum of 6 tab per dispensing and not more than one prescription per month – may be waived by Special Authority • Pharmacy services (BSF Zapril) brand switch fee – no patient co-payment payable – may only be claimed once per patient per fee Changes to restrictions (pages 24-26) • Blood glucose diagnostic test strip (CareSens and On Call Advanced) blood glucose test strips x 50 and lancets x 5 – change in pack size from 1 OP to 50 test OP. The Pharmacodes for these packs have also changed • Imiglucerase (Cerezyme) inj 40 iu per ml, 400 iu vial – removal of Section 29 • Cilazapril (Zapril) tab 0.5 mg, 2.5 mg and 5 mg – a brand switch fee may be dispensed form 1 March 2011 until 31 May 2011 • Sildenafil (Viagra) tab 25 mg, 50 mg and 100 mg – amended Special Authority criteria • Influenza vaccine (Fluvax and Fluvarix) inj – Hospital pharmacy (Xpharm) – amended access criteria • Varenicline tartrate (Champix) tab 0.5 mg x 11 and 1 mg x 14 – change in pack size from 1 OP to 25 OP. The pharmacode for this pack has also changed • Gemcitabine hydrochloride inj 200 mg and 1 g (Gemcitabine Ebewe and Gemzar) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria Increased subsidy (page 36) • Potassium chloride (AstraZeneca) inj 75 mg per ml, 10 ml • Neostigmine (AstraZeneca) inj 2.5 mg per ml, 1 ml • Lithium carbonate (Priadel) tab long-acting 400 mg

4 Pharmaceutical Schedule - Update News

Pack size Changes – Champix and blood glucose test strips with lancets

New pack sizes for Champix starter pack and the blood glucose test strips with lancets, CareSens and On Call Advanced, will be listed in the Pharmaceutical Schedule from 1 March 2011. These products will now be listed as 25 OP (Champix) and 50 OP (CareSens and On Call Advanced) rather than 1 OP. This change is intended to eliminate the overpayments that have sometimes resulted from pharmacists inadvertently claiming multiple packs instead of 1 OP. The new Pharmacodes for these products are:

• Champix tab 0.5 mg x 11 and 1 mg x 14 – 2380455 • CareSens blood glucose test strips x 50 and lancets x 5 – 2380579 • On Call Advanced blood glucose test strips x 50 and lancets x 5 – 2380447 The existing Pharmacodes for the 1 OP packs will not be able to be claimed on from 1 March 2011.

Gemcitabine hydrochloride – widening of access

The Special Authority criteria for the inhospital cancer treatment gemcitabine hydrochloride will be widened from 1 March 2011. This will mean that a greater number of patients will have access to funded treatment. The changes for subsidised access to gemcitabine hydrochloride (Gemcitabine Ebewe and Gemzar) 200 mg and 1 g and (Baxter) 1 mg for ECP injections include widening of funding to include patients with locally advanced or metastatic cholangiocarcinoma; and patients with macroscopically resected pancreatic cancer. The Gemcitabine Ebewe is currently the Hospital Supply Status brand of gemcitabine hydrochloride.

Pharmaceutical Schedule - Update News

Pharmacy Brand Switch Payments

Brand switch payments for pharmacies will be payable for dispensings of all strengths of the Zapril brand of cilazapril tablets from 1 March 2011. The brand switch fee is claimable via a Pharmacode on the first dispensing of cilazapril after 1 March 2011 for patients who have switched brands. Pharmacies should claim a fee even if the patient switched to the Sole Supply brand prior to 1 March 2011. The brand switch fees for cilazapril will be paid only once for each patient during the claim period. The brand switch fee will not be able to be claimed for this pharmaceutical for dispensing after 31 May 2011. Brand switch posters, leaflets and prescription bags are available free of charge. To order please go to www. pharmaconline.co.nz

Cefaclor capsules – Tender News

Cefaclor 250 mg capsules (Cefaclor Sandoz) will be listed fully subsidised from 1 March 2011 as a result of a Tender agreement. This decision had previously been notified to the market in October 2010; however, the listing of Sandoz’s product was delayed due to issues with stock availability. A further shipment of Ranbaxy-Cefaclor will be released into the market in mid to late March. Because of this, reference pricing will be delayed to give pharmacies time to dispense the Ranbaxy-Cefaclor brand. Reference pricing will occur on the RanbaxyCefaclor brand from 1 June 2011 and Cefaclor Sandoz will have Sole Supply Status from 1 September 2011. The RanbaxyCefaclor brand of cefaclor 250 mg capsules will be delisted from 1 September 2011.

Pharmaceutical Schedule - Update News

Diabetes Nurse Prescribing

The Ministry of Health has informed PHARMAC that it intends to give a group of 12 Diabetes Nurses in 4 DHB sites prescribing rights for a specified list of medicines and medical devices from early March 2011 until 30 September 2011. This project is initiated by Health Workforce New Zealand, on behalf of the Ministry of Health, and The Nursing Council of New Zealand under a directive from the Minister of Health. Regulations are expected to designate the nurses as prescribers and the General Rules of the Pharmaceutical Schedule have been amended to allow subsidy for prescriptions written by the 12 registered nurses practising in diabetes health.

District Health Board Auckland Registered Nurse Practising in Diabetes Health Patricia Ball Mele Kaufusi Jennifer Britland Andrea Rooderkerk Heather Charteris Tony Loversuch Mary Meendering Alison Fellerhoff Pauline Giles Kerrie Skeggs Anne-Marie Heffernan Hazel Phillips Nursing Council registration number 052157 114474 060927 117987 117839 138813 108408 064890 108269 112025 148903 160328

A further fax communication will be sent to community pharmacies once the legislation has been passed. It will announce the start date and list of medicines and devices. The 4 DHB’s demonstration sites are Auckland, Hawkes Bay, Mid Central and Hutt Valley. Pharmacies in these regions should make themselves familiar with the names of the diabetes nurses permitted to prescribe. These are listed below. For the list of medicines and medical devices that the above registered nurses practising in diabetes health may prescribe please refer to page 38 of this Update.

Hawke's Bay

Mid Central

Hutt Valley

Pharmaceutical Schedule - Update News

Cerezyme – removal of Section 29 status

Cerezyme injection 40 iu per ml, 400 iu vial has been granted Ministerial Approval and no longer needs to be supplied under Section 29 of the Medicines Act 1981.

Klacid – new pack size

From 1 March Klacid (clarithromycin) 250 mg tablets will come in a larger pack size of 14 tablets rather than 10 tablets. The smaller pack size will be delisted from 1 September 2011.

Lanoxin PG – new pack size

From 1 March Lanoxin PG (digoxin) 62.5 μg tablets will be supplied in a new pack size of 240 tablets. This is due to the 250 pack size being discontinued internationally. The new pack size will also be in blisters, strips of 30, rather than in bottles.

tender News

Sole Subsidised Supply changes – effective 1 April 2011

Chemical Name Captopril Captopril Captopril Vitamins Presentation; Pack size Tab 12.5 mg; 100 tab Tab 25 mg; 100 tab Tab 50 mg; 100 tab Tab (BPC cap strength); 1,000 tab Sole Subsidised Supply brand (and supplier) m-Captopril (Multichem) m-Captopril (Multichem) m-Captopril (Multichem) MultiADE (Boucher and Muir)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 april 2011 • Brand Switch Fees – m-Captopril (Captopril) tab • Bortezomib inj 3.5 mg (Velcade) and 1 mg for ECP (Baxter) – new listing – PCT only – Specialist – Special Authority – for multiple myeloma • Busulphan (Myleran) tab 2 mg – price and subsidy increase • Fludrocortisone acetate (Florinef) tab 100 μg – price and subsidy increase • Metoprolol succinate (Myloc CR) modified release tablets 23.75 mg, 47.5 mg, 95 mg and 190 mg – new listing • Sotalol (Sotacor) inj 10 mg per ml, 4 ml – price and subsidy increase • Sumatriptan injection (Arrow-Sumatriptan) 12 mg per ml, 0.5 ml, 2 OP - new listing – Retail pharmacy-Specialist – Maximum of 10 inj per prescription • Thalidomide (Thalomid) cap 50 mg and 100 mg – new listing – PCT only – Specialist – Special Authority – Only on a controlled drug form • Thalidomide (Thalomid and Thalidomide Pharmion) – change to Special Authority criteria • Triamcinolone acetonide with gramicidin, neomycin and nystatin (Kenacomb) ear drops, 7.5 ml OP – price and subsidy increase Possible decisions for implementation 1 april 2011 – Special foods • Elemental Formula to be separated into Extensively Hydrolysed Formula and Amino Acid Formula, with separate Special Authority criteria • Subsidy changes for the range of Extensively Hydrolysed Formula and Amino Acid Formula products • Price reduction for Neocate and Neocate LCP • Delisting of goats’ milk, soy milk and lactose free infant formula products

Possible decisions for implementation 1 april 2011 – Special foods (continued) • “Adult Products Standard” and “Oral Supplements” groups replaced with “Standard Supplements” with new Special Authority criteria • Subsidy reduction for products within the Standard Supplements group • Amend the Special Authority for Subsidy that applies to Diabetic Products • Remove the distinction between use of special foods as a supplement or as a complete diet • Amend the Special Authority for Subsidy that applies to Foods and Supplements for Inborn Errors of Metabolism A full notification of the changes affecting Special Foods funding and access is anticipated to be distributed late February 2011. This will be available on the PHARMAC website under notifications http://www.pharmac.govt.nz/ healthpros/notification.

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Acarbose Acetazolamide Aciclovir Allopurinol Amantadine hydrochloride Amlodipine Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Tab 5 mg & 10 mg Cap 250 mg & 500 mg Grans for oral liq 250 mg per 5 ml Drops 125 mg per 1.25 ml Inj 250 mg, 500 mg & 1 g

Brand Name Expiry Date*

Glucobay Diamox Lovir Apo-Allopurinol Symmetrel Apo-Amlodipine Alphamox Ospamox Ospamox Paediatric Drops Ibiamox Curam Curam Synermox AFT Vitala-C Ethics Aspirin EC Ethics Aspirin Atenolol Tablet USP AstraZeneca Imuprine Imuran Arrow-Azithromycin Pacifen ArrowBendrofluazide Sandoz Beta Scalp Fibalip Bicalox Lax-Tab AFT healthE API 2011 2011 2013 2013 2012 2012 2013 2012 2012 2011 2011 2012 2011 2011 2013 2011 2012 2012 2011 2013 2011 2011 2011 2013 2012 2011

Amoxycillin clavulanate

Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab 100 mg Tab 100 mg Tab dispersible 300 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 50 mg Inj 50 mg Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 1 mega u Scalp app 0.1% Tab 200 mg Tab 50 mg Tab 5 mg Eye drops 0.2% Crm, aqueous, BP Lotn, BP

2012

Aqueous cream Ascorbic acid Aspirin Atenolol Atropine sulphate Azathioprine Azithromycin Baclofen Bendrofluazide Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Calamine

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Calcitonin Calcitriol Calcium carbonate

Presentation

Inj 100 iu per ml, 1 ml Cap 0.25 µg & 0.5 µg Tab 1.25 g (500 mg elemental) Tab 1.5 g (600 mg elemental) Tab eff 1.7 g (1 g elemental) Inj 50 mg Oral liq 5 mg per ml Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 500 mg Inj 1 g Inj 750 mg & 1.5 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 10 mg Oral liq 1 mg per ml Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Soln 4% Nail soln 8% Tab 0.5 mg, 2.5 mg & 5 mg Tab 5 mg with hydrochlorothiazide 12.5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg Crm 0.05% Oint 0.05% Scalp app 0.05% Tab 500 µg & 2 mg TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Tab 75 mg

Brand Name Expiry Date*

Miacalcic Airflow Calci-Tab 500 Calci-Tab 600 Calsource Calcium Folinate Ebewe Capoten Ranbaxy-Cefaclor Hospira Veracol Aspen Ceftriaxone Zinacef Cefalexin Sandoz Cefalexin Sandoz Zetop Cetirizine-AFT PSM Chlorafast Chlorsig healthE Orion Batrafen Zapril Inhibace Plus Rex Medical Arrow-Citalopram Dermol Dermol Dermol Paxam Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Apo-Clopidogrel 2011 2012 2011

Calcium folinate Captopril Cefaclor monohydrate Cefazolin sodium Ceftriaxone sodium Cefuroxime sodium Cephalexin monohydrate Cetirizine hydrochloride Cetomacrogol Chloramphenicol Chlorhexidine gluconate Ciclopiroxolamine Cilazapril Cilazapril with hydrochlorothiazide Ciprofloxacin Citalopram Clobetasol propionate

2011 2013 2013 2011 2013 2011 2012 2011 2013 2012 2012 2011 2012 2013 2013 2011 2011 2012

Clonazepam Clonidine

2011 2012

Clonidine hydrochloride

2012

Clopidogrel

2013

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Clotrimazole

Presentation

Vaginal crm 1% with applicator Vaginal crm 2% with applicator Crm 1% Soln BP Tab 500 µg Crm 10% Tab 50 mg Tab 50 mg Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs Nasal spray 10 µg per dose Eye drops 0.1% Inj 4 mg per ml, 1 ml & 2 ml Inj 50%, 10 ml Soln with electrolytes

Brand Name Expiry Date*

Clomazol Clomazol Clomazol Midwest Colgout Itch-Soothe Nausicalm Cycloblastin Siterone Ginet 84 Desmopressin-PH&T Maxidex Hospira Biomed Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain Diclofenac Sandoz Voltaren Ophtha Voltaren Voltaren DHC Continus Dilzem Cardizem CD Pytazen SR Laxofast 50 Laxofast 120 Laxsol Donepezil-Rex AFT Arrow-Enalapril Clexane Comtan 2013 2011 2013 2013 2012 2012 2013 2012 2011 2011 2013 2013 2011 2013

Coal tar Colchicine Crotamiton Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone Dexamethasone sodium phosphate Dextrose Dextrose with electrolytes

Diclofenac sodium

Tab EC 25 mg & 50 mg Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 50 mg with total sennosides 8 mg Tab 5 mg & 10 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg

2012 2011

Dihydrocodeine tartrate Diltiazem hydrochloride

2013 31/12/11

Dipyridamole Docusate sodium Docusate sodium with sennosides Donepezil hydrochloride Emulsifying ointment Enalapril Enoxaparin sodium (low molecular weight heparin) Entacapone

2011 2011 2013 2012 2011 2012 2012 2012

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Erythromycin ethyl succinate

Presentation

Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 10 mg & 20 mg Tab 10 µg Tab 200 mg Tab long-acting 5 mg Tab long-acting 10 mg Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) Tab 5 mg Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Inj 50 mg Tab 10 mg Eye drops 0.1% Cap 20 mg Tab dispersible 20 mg, scored Tab 250 mg Metered aqueous nasal spray, 50 µg per dose Inj 10 mg per ml, 2 ml Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Tab 600 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Liquid Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

E-Mycin E-Mycin E-Mycin Loxalate NZ Medical and Scientific Arrow-Etidronate Felo 5 ER Felo 10 ER Ferodan Fintral AFT AFT AFT Flucloxin Pacific Fludara Fludara Oral FML Fluox Fluox Flutamin Flixonase Hayfever & Allergy Frusemide-Claris Diurin 40 Foban Foban Nupentin Lipazil Pfizer Apo-Gliclazide Minidiab healthE Lycinate Nitrolingual Pumpspray Nitroderm TTS 2012 2011 2013 2012 2012 2012 2013 2011 2012 2011 2011 2011 2012 2013 2013 31/1/13 2013 2012 2013 31/7/12 2013 2012 2011 2011 2013 2011

Escitalopram Ethinyloestradiol Etidronate disodium Felodipine Ferrous sulphate Finasteride Flucloxacillin sodium

Fluconazole Fludarabine phosphate Fluorometholone Fluoxetine hydrochloride Flutamide Fluticasone propionate Furosemide Fusidic acid Gabapentin Gemfibrozil Gentamicin sulphate Gliclazide Glipizide Glycerol Glyceryl trinitrate

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Haloperidol

Presentation

Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 50 mg per ml, 1 ml Tab 5 mg & 20 mg Powder Crm 1%, 500 g Rectal foam 10%, CFC-free (14 applications) Crm 1% with miconazole nitrate 2% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Oral liq 100 mg per 5 ml Tab 200 mg Tab 2.5 mg Nebuliser soln, 250 µg per ml, 1 ml & 2 ml Inj 50 mg per ml, 2 ml Cap 10 mg & 20 mg Shampoo 2% Oral liq 10 mg per ml Tab 150 mg Eye drops 50 µg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Inj 1%, 5 ml & 20 ml Crm 2.5% with prilocaine 2.5% (5 g tubes) Crm 2.5% with prilocaine 2.5%; 30 g OP Tab 5 mg, 10 mg & 20 mg Cap 2 mg Oral liq 1 mg per ml Tab 10 mg

Brand Name Expiry Date*

Serenace Serenace Serenace Solu-Cortef Douglas ABM PSM Colifoam Micreme H DP Lotn HC ABM Hydroxocobalamin Plaquenil Methopt Buscopan Gastrosoothe Fenpaed Ethics Ibuprofen Dapa-Tabs Univent Ferrum H Oratane Sebizole 3TC 3TC Hysite Letara Jadelle Xylocaine EMLA EMLA Arrow-Lisinopril Diamide Relief Lorapaed Loraclear Hayfever Relief 2012 2013 2013 2013

Hydrocortisone

2013 2012 2011 2012 2013 2011 2012 2012 2011 2011 2013 2012 2013 2013 2011 2012 2011 2013 2012 2012 31/12/13 2013 2013

Hydrocortisone acetate Hydrocortisone with miconazole Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hypromellose Hysocine N-butylbromide Ibuprofen Indapamide Ipratropium bromide Iron polymaltose Isotretinoin Ketoconazole Lamivudine Latanoprost Letrozole Levonorgestrel Lignocaine hydrochloride Lignocaine with prilocaine

Lisinopril Loperamide hydrochloride Loratadine

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Lorazepam Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Megestrol acetate Mercaptopurine Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Tab 1 mg & 2.5 mg Liq 0.5% Shampoo 1% Device Tab 100 mg Tab 135 mg Tab 160 mg Tab 50 mg Enema 1 g per 100 ml Tab immediate-release 500 mg & 850 mg Tab 5 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 25 mg per ml, 2 ml & 20 ml Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml & 50 ml Tab 125 mg, 250 mg & 500 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Inj 5 mg per ml, 2 ml Crm 2% Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg Tab immediate release 10 mg & 20 mg Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml

Brand Name Expiry Date*

Ativan A-Lices A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Apo-Megestrol Purinethol Pentasa Apotex Methatabs Biodone Biodone Forte Biodone Extra Forte Hospira Methoblastin Methotrexate Ebewe Prodopa Medrol Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Multichem Apo-Moclobemide m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph m-Elson Sevredol Mayne Mayne 2013 2013 30/9/11 2011 2011 2012 2013 2012 2012 2013 2012

Methotrexate

2013 2012 2011 2011 2012 2011 2011 2012

Methyldopa Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate

Metoclopramide hydrochloride Miconazole nitrate Moclobemide Mometasone furoate Morphine hydrochloride

2011 2011 2012 2012 2012

Morphine sulphate

2013 2012 2011

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Morphine tartrate Mucilaginous laxatives Naproxen Nevirapine

Presentation

Inj 80 mg per ml, 1.5 ml & 5 ml Dry Tab 250 mg Tab 500 mg Oral suspension 10 mg per ml Tab 200 mg

Brand Name Expiry Date*

Hospira Konsyl-D Noflam 250 Noflam 500 Viramune Suspension Viramune Noriday 28 Primolut N Norpress Nilstat Nilstat Nilstat Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Dr Reddy’s Pantoprazole Pharmacare Paracare Junior Paracare Double Strength ParaCode Lacri-Lube Loxamine Breath-Alert 2013 2013 2012 2012

Norethisterone Nortriptyline hydrochloride Nystatin

Tab 350 µg Tab 5 mg Tab 10 mg & 25 mg Cap 500,000 u Tab 500,000 u Oral liq 100,000 u per ml, 24 ml OP Cap 10 mg, 20 mg & 40 mg Inj 40 mg

2012 2011 2011 2013 2011 2011

Omeprazole

Oxytocin

Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 20 mg & 40 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Eye oint with soft white paraffin Tab 20 mg Low range and Normal range

2012

Pamidronate disodium

2011

Pantoprazole Paracetamol

2013 2011

Paracetamol with codeine Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak Flow Meter

2011 2013 2013 30/9/11

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Pegylated interferon alpha-2A

Presentation

Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Tab 0.25 mg & 1 mg Lotn 5% Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 µg Oral drops 10% Eye drops 1.4% Eye drops 3% Tab long-acting 600 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg Oral liq 5 mg per ml Cassette Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg

Brand Name Expiry Date*

Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax A-Scabies Cilicaine VK AFT AFT Apo-Pindolol Pizaccord Sandomigran Coloxyl Vistil Vistil Forte Span-K Apo-Prednisone Redipred Innovacon hCG One Step Pregnancy Test Cilicaine Promethazine Winthrop Elixir Allersoothe Accupril Accuretic 10 Accuretic 20 Q 300 Mycobutin Ropin ArrowRoxithromycin 2012 2013 2013 2012 2012 2012 2012 2011 2011 2012 2011 2012 2012 2011 2012 2011 2011 2011 31/12/12

Pergolide Permethrin Phenoxymethylpenicillin (Pencillin V)

2011 2011 2013

Pindolol Pioglitazone Pizotifen Poloxamer Polyvinyl alcohol Potassium chloride Prednisone Prednisone sodium phosphate Pregnancy tests – hCG urine Procaine penicillin Promethazine hydrochloride

Quinapril Quinapril with hydrochlorothiazide

Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Tab 300 mg Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg & 5 mg Tab 150 mg & 300 mg

Quinine sulphate Rifabutin Ropinirole hydrochloride Roxithromycin

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Salbutamol

Presentation

Oral liq 2 mg per 5 ml Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Grans effervescent 4 g sachets Eye drops 2% Nasal spray, 4% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 80 mg & 160 mg 230 ml, autoclavable & single patient Tab 25 mg & 100 mg Tab 50 mg & 100 mg Cap 400 µg Soln 2.3% Tab 10 mg Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Inj 250 µg Inj 1 mg per ml, 1 ml Tab 10 mg Eye drops 0.25% & 0.5% Cap 50 mg Tab 500 mg

Brand Name Expiry Date*

Salapin Asthalin Asthalin Duolin 2013 2012 2012

Salbutamol with ipratropium bromide Selegiline hydrochloride Sertraline Simvastatin

Apo-Selegiline Arrow-Sertraline Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Biomed Micolette Ural Rexacrom Rex Genotropin Genotropin Mylan Space Chamber Spirotone Arrow-Sumatriptan Tamsulosin-Rex Pinetarsol Normison Arrow Apo-Terbinafine Depo-Testosterone Arrow-Testosterone Synacthen Synacthen Depot Apo-Timol Apo-Timop Arrow-Tramadol Cycklokapron

2012 2013 2011

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cromoglycate Somatropin Sotalol Spacer Device Spironolactone Sumatriptan Tamsulosin hydrochloride Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terazosin hydrochloride Terbinafine Testosterone cypionate Testosterone undecanoate Tetracosactrin Timolol maleate Tramadol hydrochloride Tranexamic acid

2013 2013 2013 2013 2012 31/12/12 2012 30/9/11 2013 2013 2013 2011 2011 2013 2011 2011 2012 2011 2012 2011 2011 2013

Sole Subsidised Supply Products – cumulative to March 2011

Generic Name

Triamcinolone acetonide

Presentation

Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 5 mg Cap 300 mg Inj 50 mg per ml, 10 ml Tab, strong, BPC Cap 100 mg Oral liq 10 mg per ml Oint BP Cap 137.4 mg (50 mg elemental) Tab 7.5 mg

Brand Name Expiry Date*

Aristocort Aristocort Kenacort-A40 Oracort TMP Navoban Actigall Pacific B-PlexADE Retrovir Retrovir PSM Zincaps Apo-Zopiclone 2011

Trimethoprim Tropisetron Ursodeoxycholic acid Vancomycin hydrochloride Vitamin B complex Zidovudine [AZT] Zinc and castor oil Zinc sulphate Zopiclone March changes in bold

2011 2012 2011 2011 2013 2013 2011 2011 2011

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 March 2011

28 50 82 83 94 94 127 LANSOPRAZOLE ❋ Cap 15 mg ................................................................................ 3.27 ❋ Cap 30 mg ................................................................................ 4.34 DIGOXIN ❋ Tab 62.5 µg – Up to 30 tab available on a PSO .......................... 6.67 CEFACLOR MONOHYDRATE Cap 250 mg ............................................................................ 24.57 28 28 240 100 ✔ Lanzol Relief ✔ Lanzol Relief ✔ Lanoxin PG ✔ Cefaclor Sandoz

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0988 Tab 250 mg .............................................................................. 7.75 14 ✔ Klacid DARUNAVIR – Special Authority see SA1025 – Retail pharmacy Tab 600 mg ....................................................................... 1,190.00 RITONAVIR – Special Authority see SA1025 – Retail pharmacy Tab 100 mg ............................................................................ 43.31 60 30 ✔ Prezista ✔ Norvir

ONDANSETRON a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 c) Not more than one prescription per month; can be waived by Special Authority see SA0887. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab disp 4 mg ........................................................................... 1.70 10 ✔ Dr Reddy’s Ondansetron Tab disp 8 mg ........................................................................... 2.00 10 ✔ Dr Reddy’s Ondansetron PHARMACY SERVICES – May only be claimed once per patient ❋ Brand switch fee ....................................................................... 0.01 The Pharmacode for BSF Zapril is 2378639 (BSF Zapril Brand switch fee to be delisted 1 June 2011) 1 fee ✔ BSF Zapril

171

Effective 1 February 2011

73 POTASSIUM CITRATE Oral liq 3 mmol per ml – Special Authority see SA1083 – Retail pharmacy................................................................ 30.00 200 ml OP ✔ Biomed

➽ SA1083 Special Authority for Subsidy Initial application only from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has recurrent calcium oxalate urolithiasis; and 2 The patient has had more than two renal calculi in the two years prior to the application. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 February 2011 (continued)

77 OESTRADIOL – See prescribing guideline ❋ TDDS 25 µg per day ................................................................. 3.01 (10.86) a) Higher subsidy of $10.86 per 8 patch with Special Authority see SA1018 b) No more than 2 patch per week c) Only on a prescription ❋ TDDS 100 µg per day ............................................................... 7.05 (16.14) a) Higher subsidy of $16.14 per 8 patch with Special Authority see SA1018 b) No more than 2 patch per week c) Only on a prescription LINCOMYCIN – Retail pharmacy-Specialist Inj 300 mg per ml, 2 ml ........................................................... 80.00 FENTANYL a) Only on a controlled drug form b) No patient co-payment payable Transdermal patch 12.5 µg per hour ......................................... 8.90 Transdermal patch 25 µg per hour ............................................ 9.15 Transdermal patch 50 µg per hour .......................................... 11.50 Transdermal patch 75 µg per hour .......................................... 13.60 Transdermal patch 100 µg per hour ........................................ 14.50 164 SALBUTAMOL WITH IPRATROPIUM BROMIDE Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose CFC-free ..................................................................... 12.19 SODIUM CHLORIDE Soln 7% .................................................................................. 23.50 CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml) ............................... 14.85 PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee ....................................................................... 0.01 The Pharmacode for BSF Apo-Clopidogrel is 2378655 (BSF Apo-Clopidogrel Brand switch fee to be delisted 1 May 2011) 8 Estradot

8 Estradot

86 117

✔ Lincocin S29

5 5 5 5 5

✔ Mylan Fentanyl Patch ✔ Mylan Fentanyl Patch ✔ Mylan Fentanyl Patch ✔ Mylan Fentanyl Patch ✔ Mylan Fentanyl Patch

200 dose OP ✔ Duolin HFA 90 ml OP 25 ml OP 1 fee ✔ Biomed ✔ Biomed ✔ BSF Apo-Clopidogrel

164 165 171

Effective 1 January 2011

34 43 LACTULOSE – Only on a prescription ❋ Oral liq 10 g per 15 ml .............................................................. 7.68 SODIUM CHLORIDE Inj 0.9%, 5 ml – Up to 5 inj available on a PSO ......................... 10.85 Inj 0.9%, 10 ml – Up to 5 inj available on a PSO ....................... 11.50 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. 1,000 ml 50 50 ✔ Laevolac ✔ Multichem ✔ Multichem

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 January 2011 (continued)

98 INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available 1 March until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obsese d) children aged over 6 months and under 5 years who are from high deprivation backgrounds The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj .......................................................................................... 90.00 10 ✔ Fluvax ✔ Fluarix NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. Gum 2 mg (Classic) ............................................................... 14.97 96 Gum 4 mg (Classic) ............................................................... 20.02 96

142

✔ Habitrol ✔ Habitrol

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 January 2011 (continued)

171 PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Imuprine is 2377829 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Dapa-Tabs is 2377837 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Univent is 2377845 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Arrow Terazosin is 2377853 (BSF Imuprine to be delisted 1 April 2011) (BSF Dapa-Tabs to be delisted 1 April 2011) (BSF Univent to be delisted 1 April 2011) (BSF Arrow Terazosin to be delisted 1 April 2011) 1 fee 1 fee 1 fee 1 fee ✔ BSF Imuprine ✔ BSF Dapa-Tabs ✔ BSF Univent ✔ BSF Arrow Terazosin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 March 2011

31 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood glucose test strips × 50 and lancets × 5 ...................... 19.10 50 test OP 1 OP✔ On Call Advanced 19.60 ✔ CareSens Note – pack size change from 1 OP to 50 test OP. The pharmacodes for these packs have also changed. IMIGLUCERASE – Special Authority see SA0473 – Retail pharmacy Inj 40 iu per ml, 400 iu vial ................................................ 2,144.00 CILAZAPRIL – Brand switch fee payable ❋ Tab 0.5 mg .............................................................................. 0.95 ❋ Tab 2.5 mg .............................................................................. 2.06 ❋ Tab 5 mg ................................................................................. 3.28 1 30 30 30 ✔ Cerezyme S29 ✔ Zapril ✔ Zapril ✔ Zapril

35 48 56

SILDENAFIL – Special Authority see SA1086 0968 – Retail pharmacy Tab 25 mg ............................................................................. 52.00 4 ✔ Viagra Tab 50 mg ............................................................................. 59.50 4 ✔ Viagra Tab 100 mg ........................................................................... 68.00 4 ✔ Viagra Note – Change to criteria. Application details may be obtained from PHARMAC’s website http://www.pharmac. govt.nz or The Coordinator, PAH Panel. INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available 1 March until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)diabetes; iv)chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi)the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin, or. continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2011 (continued)

continued... h) pregnancy. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obsese d) children aged over 6 months and under 5 years who are from high deprivation backgrounds The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj .......................................................................................... 90.00 10 ✔ Fluvax ✔ Fluarix

141

VARENICLINE TARTRATE – Special Authority see SA1054 – Retail pharmacy Tab 0.5 mg × 11 and 1 mg × 14 .......................................... 60.48 25 OP 1 OP ✔ Champix Note – pack size change from 1 OP to 25 tab OP. The pharmacode for this pack has also changed. GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1087 1012 Inj 1 g .................................................................................... 62.50 1 ✔ Gemcitabine Ebewe 349.20 ✔ Gemzar Inj 200 mg ............................................................................. 12.50 1 ✔ Gemcitabine Ebewe 78.00 ✔ Gemzar Inj 1 mg for ECP ....................................................................... 0.07 1 mg ✔ Baxter ➽ SA1087 1012 Special Authority for Subsidy Initial application — (Hodgkin’s Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has Hodgkin’s Disease*; and 2 Any of the following: 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or 2.2 Disease has relapsed following transplant; or 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and 3 Gemcitabine to be given for a maximum of 6 treatment cycles. Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has T-cell Lymphoma*; and 2 Gemcitabine to be given for a maximum of 6 treatment cycles. Note: Indications marked with a * are Unapproved Indications. Initial application — (Cholangiocarcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: continued...

145

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2011 (continued)

continued... Both: 1 The patient has locally advanced or metastatic, cholangiocarcinoma*; and 2 Gemcitabine to be given for a maximum of 8 treatment cycles. Notes: Cholangiocarcinoma encompasses epithelial tumours of the hepatobiliary tree, including tumours of bile ducts, ampulla of vater and gallbladder. Indications marked with a * are Unapproved Indications. Initial application — (Pancreatic Cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either 1 Both: 1.1 The patient has macroscopically resected (R0) pancreatic carcinoma*; and 1.2 Adjuvant gemcitabine to be administered for a maximum of 6 cycles; or 2 Both: 2.1 The patient has advanced pancreatic carcinoma; and 2.2 The patient is gemcitabine treatment naïve. Note: Indications marked with a * are Unapproved Indications. Renewal - (Pancreatic Cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has received gemcitabine for advanced pancreatic carcinoma; and 2 The patient has not received gemcitabine for adjuvant treatment pancreatic carcinoma; and 3 The patient requires continued therapy. Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or 2 The patient has advanced malignant mesothelioma; or 3 The patient has advanced pancreatic carcinoma; or 3 4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or 4 5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Note: Indications marked with a * are Unapproved Indications. Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.

Effective 1 February 2011

41 CLOPIDOGREL – Brand switch fee payable Tab 75 mg ............................................................................... 5.05 16.25 FENTANYL – Special Authority see SA0935 – Retail pharmacy a) Only on a controlled drug form b) No patient co-payment payable Transdermal patch, matrix 25 µg per hour – Special Authority see SA1080 – Retail pharmacy .......................................... 55.23

S29

28 90

✔ Apo-Clopidogrel ✔ Apo-Clopidogrel

117

✔ Durogesic continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 February 2011 (continued)

continued... Transdermal patch, matrix 50 µg per hour – Special Authority see SA1080 – Retail pharmacy ........................................ 100.52 Transdermal patch, matrix 75 µg per hour – Special Authority see SA1080 – Retail pharmacy ........................................ 139.18 Transdermal patch, matrix 100 µg per hour – Special Authority see SA1080 – Retail pharmacy ........................................ 171.22 5 5 5 ✔ Durogesic ✔ Durogesic ✔ Durogesic

➽ SA1080 0935 Special Authority for Subsidy Notes: Subsidy for patients pre-approved by PHARMAC on 1 February 2011. Approvals valid for 6 months. No new approvals will be granted from 1 February 2011. Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated. Renewal from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. 132 RISPERIDONE – Special Authority see SA0926 – Retail pharmacy Inj Microspheres for injection 25 mg per 2 ml ....................... 175.00 Inj Microspheres for injection 37.5 mg per 2 ml .................... 230.00 Inj Microspheres for injection 50 mg per 2 ml ....................... 280.00 1 1 1 ✔ Risperdal Consta ✔ Risperdal Consta ✔ Risperdal Consta

➽ SA0926 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had less than 12 months treatment with risperidone depot injection microspheres; and 1.2 There is no clinical reason to discontinue treatment; or 2 The initiation of risperidone depot injection microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection microspheres. Note: Risperidone depot injection microspheres should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection microspheres.

continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011

47 54 86 TERAZOSIN HYDROCHLORIDE – Brand switch fee payable ❋ Tab 1 mg ................................................................................. 1.50 ❋ Tab 2 mg ................................................................................. 0.80 ❋ Tab 5 mg ................................................................................. 1.00 INDAPAMIDE – Brand switch fee payable ❋ Tab 2.5 mg .............................................................................. 2.95 28 28 28 90 ✔ Arrow ✔ Arrow ✔ Arrow ✔ Dapa-Tabs

MOXIFLOXACIN – Special Authority see SA1065 – Retail pharmacy – No patient co-payment payable Tab 400 mg ........................................................................... 52.00 5 ✔ Avelox ➽ SA1065 Special Authority for Subsidy Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Active tuberculosis*; and 1.2 Any of the following: 1.2.1 Documented resistance to one or more first-line medications; or 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*. Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

DAPSONE – No patient co-payment payable Tab 25 mg ............................................................................. 95.00 Tab 100 mg ......................................................................... 110.00 BROMOCRIPTINE MESYLATE ❋ Cap 5 mg ............................................................................... 60.43 GABAPENTIN – Special Authority see SA1071 1009– Retail pharmacy ▲ Cap 100 mg ............................................................................. 7.16 ▲ Cap 300 mg ........................................................................... 11.50 ▲ Cap 400 mg ........................................................................... 14.75

100 100 100

✔ Dapsone S29 ✔ Dapsone S29 ✔ Apo-Bromocriptine

S29

115 123

100 100 100

✔ Nupentin ✔ Nupentin ✔ Nupentin

➽ SA1071 1009 Special Authority for Subsidy Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin; or 2 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents, or seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant. Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site. Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site. Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

125 VIGABATRIN – Special Authority see SA1072 1010 – Retail pharmacy ▲ Tab 500 mg ......................................................................... 119.30 100 ✔ Sabril

➽ SA1072 1010 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient has infantile spasms; or 1.2 Both: 1.2.1 Patient has epilepsy; and 1.2.2 Either: 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and 2 Either: 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or 2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Note: Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

137 DEXAMPHETAMINE SULPHATE – Special Authority see SA1073 0907 – Retail pharmacy Only on a controlled drug form Tab 5 mg ............................................................................... 16.50 100 ✔ PSM ➽ SA1073 0907 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Both: 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 3.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients 5 or over - patient has had an approval for dexamphetamine for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application — (ADHD in patients under 5 - patient has had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Initial application —(Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy. Initial application — (Narcolepsy - patient has had an approval for dexamphetamine for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... 2.2.2 Provide name of the recommending specialist. Note: If the patient had an approval for dexamphetamine for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for dexamphetamine for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. 138 METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA1074 0908 – Retail pharmacy Only on a controlled drug form Tab immediate-release 5 mg ..................................................... 3.20 30 ✔ Rubifen Tab immediate-release 10 mg ................................................... 3.00 30 ✔ Ritalin ✔ Rubifen Tab immediate-release 20 mg ................................................... 7.85 30 ✔ Rubifen Tab sustained-release 20 mg .................................................. 10.95 30 ✔ Rubifen SR 50.00 100 ✔ Ritalin SR ➽ SA1074 0908 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Both: 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 3.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients 5 or over - patient has had an approval for methylphenidate for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application — (ADHD in patients under 5 - patient has had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Initial application — (Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy. Initial application — (Narcolepsy - patient has had an approval for methylphenidate for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Note: If the patient had an approval for methylphenidate for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for methylphenidate for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. 142 NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. a) Maximum of 768 piece per prescription b) Maximum of 384 piece per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 384 piece per dispensing cannot be waived via Access Exemption Criteria. Gum 2 mg (Classic) ............................................................... 14.97 96 ✔ Habitrol Gum 2 mg (Fruit) .................................................................... 14.97 96 OP ✔ Habitrol Gum 2 mg (Mint) .................................................................... 14.97 96 OP ✔ Habitrol Gum 4 mg (Classic) ............................................................... 20.02 96 ✔ Habitrol Gum 4 mg (Fruit) .................................................................... 20.02 96 OP ✔ Habitrol Gum 4 mg (Mint) .................................................................... 20.02 96 OP ✔ Habitrol

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

142 NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. a) Maximum of 432 loz per prescription b) Maximum of 216 loz per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 216 loz per dispensing cannot be waived via Access Exemption Criteria. Lozenge 1 mg ........................................................................ 11.08 36 OP ✔ Habitrol Lozenge 2 mg ........................................................................ 11.08 36 OP ✔ Habitrol NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. a) Maximum of 56 patch per prescription b) Maximum of 28 patch per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 28 patch per dispensing cannot be waived via Access Exemption Criteria. Patch 7 mg ............................................................................ 10.53 7 OP ✔ Habitrol Patch 14 mg .......................................................................... 11.63 7 OP ✔ Habitrol Patch 21 mg .......................................................................... 12.32 7 OP ✔ Habitrol MITOMYCIN C – PCT only – Specialist Inj 5 mg ................................................................................. 72.75 TRETINOIN Cap 10 mg – PCT – Retail pharmacy-Specialist ................... 435.90 AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg – Brand switch fee payable................................... 18.45 IPRATROPIUM BROMIDE Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO – Brand switch fee payable ................................... 3.79 Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available ....... on a PSO – Brand switch fee payable ................................... 4.06 1 100 100 ✔ Arrow S29 ✔ Vesanoid ✔ Imuprine

142

149 150 156 163

20 20

✔ Univent ✔ Univent

172

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases: • Aqueous cream • Cetomacrogol cream BP • Collodion flexible • Emulsifying ointment BP • Glycerol with paraffin and cetyl alcohol lotion • Hydrocortisone with wool fat and mineral oil lotion • Oil in water emulsion • Oily cream • Urea cream 10% • White soft paraffin • Wool fat with mineral oil lotion continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... • Zinc cream BP • Zinc and castor oil ointment BP • Proprietary Topical Corticosteroid-Plain preparations

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 March 2011

34 43 99 113 LACTULOSE – Only on a prescription ( price) ❋ Oral liq 10 g per 15 ml ............................................................... 6.65 POTASSIUM CHLORIDE ( subsidy) ❋ Inj 75 mg per ml, 10 ml ........................................................... 55.00 NEOSTIGMINE ( subsidy) Inj 2.5 mg per ml, 1 ml .......................................................... 150.00 HYALURONIDASE ( price) Inj 1,500 iu per ml ................................................................... 18.32 (254.92) LITHIUM CARBONATE ( sudsidy) Tab long-acting 400 mg .......................................................... 18.50 1,000 ml 50 50 10 Hyalase 100 ✔ Priadel ✔ Duphalac ✔ AstraZeneca ✔ AstraZeneca

129

Effective 1 February 2011

34 45 46 LACTULOSE – Only on a prescription ( price) ❋ Oral liq 10 g per 15 ml .............................................................. 6.65 (7.68) EZETIMIBE – Special Authority see SA1045 – Retail pharmacy ( subsidy) Tab 10 mg ............................................................................. 45.90 1,000 ml Duphalac 30 ✔ Ezetrol

EZETIMIBE WITH SIMVASTATIN – Special Authority see SA1046 – Retail pharmacy ( subsidy) Tab 10 mg with simvastatin 10 mg ......................................... 48.90 30 ✔ Vytorin Tab 10 mg with simvastatin 20 mg ......................................... 51.60 30 ✔ Vytorin Tab 10 mg with simvastatin 40 mg ......................................... 55.20 30 ✔ Vytorin Tab 10 mg with simvastatin 80 mg ......................................... 60.60 30 ✔ Vytorin GOSERELIN ACETATE ( subsidy) Inj 3.6 mg ............................................................................ 166.20 Inj 10.8 mg .......................................................................... 443.76 ITRACONAZOLE – Retail pharmacy-Specialist ( subsidy) Cap 100 mg ............................................................................. 4.25 (23.70) 1 1 15 Sporanox ✔ Zoladex ✔ Zoladex

127

ONDANSETRON ( subsidy) a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 c) Not more than one prescription per month; can be waived by Special Authority see SA0887. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg ................................................................................. 1.70 10 (17.18) Zofran Tab 8 mg ................................................................................. 3.40 20 (33.89) Zofran

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – Effective 1 January 2011

37 VITAMINS ( subsidy) ❋ Tab (BPC cap strength) ............................................................ 8.00 (14.80) CAPTOPRIL ( subsidy) ❋ Tab 12.5 mg .......................................................................... 10.00 (10.40) ❋ Tab 25 mg ............................................................................. 12.00 (13.40) ❋ Tab 50 mg ............................................................................. 17.50 (19.00) 1,000 Healtheries Multivitamin tablets 500 Apo-Captopril 500 Apo-Captopril 500 Apo-Captopril

48 94 147

RALTEGRAVIR POTASSIUM – Special Authority see SA1025 – Retail pharmacy ( subsidy) Tab 400 mg ...................................................................... 1,090.00 60 ✔ Isentress METHOTREXATE ( subsidy) ❋ Inj 1 mg for ECP – PCT only – Specialist ................................... 0.10 1 mg ✔ Baxter

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 March 2011

14 “Diabetes Nurse Prescriber” means a registered nurse practising in diabetes health who has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site. “Nurse Prescriber” means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice including, for the avoidance of doubt, a Diabetes Nurse Prescriber. 3.6 Diabetes Nurse Prescribers’ Prescriptions The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber: 3.6.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either: a) A Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which Diabetes Nurse Prescribers is permitted under regulations to prescribe; or b) any other Community Pharmaceutical listed below, being an item that has been identified as being able to be prescribed by a Diabetes Nurse Prescriber, but which is not classified as a Prescription Medicine or a Restricted Medicine: aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip, 3.6.2 Any Diabetes Nurse Prescribers’ prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed). Note: A list of Diabetes Nurse Prescribers will be published periodically in the Update of the Pharmaceutical Schedule for the duration of an initial pilot scheme. After this period there will be no approved DHB demonstration sites and hence no Diabetes Nurse Prescribers.

Changes to Brand Name

Effective 1 March 2011

99 IBUPROFEN ❋ Tab long-acting 800 mg ........................................................... 9.12 30 ✔ Brufen SR Retard

Changes to Sole Subsidised Supply

Effective 1 March 2011

For the list of new Sole Subsidised Supply products effective 1 March 2011 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 10-19.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 March 2011

48 61 72 84 CILAZAPRIL ❋ Tab 0.5 mg .............................................................................. 0.95 (2.20) ❋ Tab 2.5 mg ............................................................................... 1.92 (4.10) ❋ Tab 5 mg ................................................................................. 3.06 (6.01) 30 Inhibace 28 Inhibace 28 Inhibace ✔ Locoid C ✔ Hospira S29

HYDROCORTISONE BUTYRATE WITH CHLORQUINALDOL – Only on a prescription Crm 0.1% with chlorquinaldol 3% .............................................. 3.49 15 g OP METHYLERGOMETRINE Inj 200 µg per ml, 1 ml – Up to 10 inj available on a PSO ........... 9.28 AMOXYCILLIN Cap 250 mg – Up to 30 cap available on a PSO ....................... 16.18 (17.30) Cap 500 mg ........................................................................... 26.50 (27.25) CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml ............................................................ 14.95 CHLORAMPHENICOL Eye drops 0.5% ........................................................................ 1.28 (2.40) 10

500 500 5 10 ml OP

Apo-Amoxi Apo-Amoxi ✔ Valoid (AFT)

127 166

Chlorsig

Effective 1 February 2011

33 MUCILAGINOUS LAXATIVES – Only on a prescription ❋ Dry ........................................................................................... 3.91 (5.72) 4.58 (6.69) 5.42 (12.71) 6.02 (16.49) ❋ Dry-original flavour, regular texture only .................................... 4.05 (12.38) Note – Konsyl-D 500 g pack remains listed fully subsidised. VITAMIN B COMPLEX ❋ Tab, strong, BPC ...................................................................... 4.70 (12.10) CLOPIDOGREL Tab 75 mg ............................................................................... 5.06 5.06 (73.38) Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. 325 g OP Konsyl-D 380 g OP Mucilax 450 g OP Isogel 500 g OP Normacol 336 g OP Metamucil

36 41

500 Apo-B-Complex 28 28 ✔ Arrow-Clopidogrel Plavix

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 February 2011 (continued)

54 80 82 FUROSEMIDE ❋ Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO ............ 13.00 (29.50) CLOMIPHENE CITRATE Tab 50 mg ............................................................................... 2.50 50 Mayne 5 ✔ Phenate

CEFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 500 mg ............................................................................... 2.57 1 (3.99) AFT INDOMETHACIN ❋ Cap long-acting 75 mg ........................................................... 13.30 SODIUM CROMOGLYCATE Eye drops 2% ........................................................................... 2.36 (3.95) PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Arrow-Enalapril is 2375613 100 10 ml OP Cromolux 1 fee ✔ BSF Arrow-Enalapril ✔ Rheumacin SR

100 167

171 184 191

ORAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital pharmacy [HP3] Liquid (strawberry) ................................................................... 1.78 237 ml OP ✔ Resource Diabetic ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid (strawberry) ................................................................... 1.33 237 ml OP ✔ Resource Plus

Effective 1 January 2011

25 SODIUM ALGINATE ❋ Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) .................................................................................. 1.50 (8.64) ZINC OXIDE Oint zinc oxide with balsam peru ............................................... 4.50 (6.67) Suppos zinc oxide with balsam peru ......................................... 4.47 (6.49)

500 ml Gaviscon 50 g OP Anusol 12 Anusol

SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml .............................................................................. 6.00 12 (7.30)

Microlax

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 January 2011 (continued)

36 ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg ........................................................................... 13.80 (17.25) MULTIVITAMINS – Special Authority see SA1036 – Retail pharmacy Powder .................................................................................. 36.00 Note – Paediatric Seravit powder 200 g OP remains subsidised. TERAZOSIN HYDROCHLORIDE ❋ Tab 1 mg ................................................................................. 1.50 (2.50) ❋ Tab 7 × 1 mg and 7 × 2 mg ................................................... 0.74 ❋ Tab 2 mg ............................................................................... 14.29 (23.30) ❋ Tab 5 mg ............................................................................... 17.86 (29.00) INDAPAMIDE ❋ Tab 2.5 mg .............................................................................. 3.25 CICLOPIROXOLAMINE a) Only on a prescription b) Not in combination Crm 1% .................................................................................... 1.00 (12.82)

500 Apo-Ascorbic Acid 100 g OP ✔ Paediatric Seravit

47 54 58

28 14 OP 500 500 Apo-Terazosin 100 ✔ Napamide Apo-Terazosin ✔ Hytrin Starter Pack Apo-Terazosin

20 g OP Batrafen

DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2% ............................................................................... 6.81 50 g OP (13.54) Prantal GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription ❋ Lotn 5% with paraffin liq 5% and cetyl alcohol 2% ..................... 1.40 250 ml (8.10) SODIUM HYPOCHLORITE – Subsidy by endorsement Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ❋ Soln ......................................................................................... 2.71 2,500 ml ZINC Crm BP .................................................................................... 6.55 (12.00) OILY CREAM ❋ Crm BP .................................................................................... 2.80 (13.60) (15.40) 500 g PSM 500 g David Craig PSM

62 62 62

✔ Janola

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 January 2011 (continued)

64 MALATHION Liq 0.5% ................................................................................... 3.79 (4.99) TAR WITH CADE OIL Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound .......... 9.70 (29.60) HYDROGEN PEROXIDE ❋ Soln 20 vol – Maximum of 500 ml per prescription .................... 0.63 (2.35) 3.13 (7.00) APPLICATOR When ordered with a spermicide. ❋ Applicator – Up to 1 dev available on a PSO ............................... 4.34 NONOXYNOL-9 Jelly 2% – Up to 108 g available on a PSO ............................... 10.95 DIAPHRAGM – Up to 1 dev available on a PSO One of each size is permitted on a PSO. ❋ 55 mm ................................................................................... 42.90 ❋ 60 mm ................................................................................... 42.90 ❋ 65 mm ................................................................................... 42.90 ❋ 70 mm ................................................................................... 42.90 ❋ 75 mm ................................................................................... 42.90 ❋ 80 mm ................................................................................... 42.90 ❋ 85 mm ................................................................................... 42.90 ❋ 90 mm ................................................................................... 42.90 200 ml OP Derbac-M 350 ml Polytar Emollient 100 ml PSM 500 ml PSM

68 68 69 82

1 108 g OP

✔ Ortho ✔ Gynol II

1 1 1 1 1 1 1 1

✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 January 2011 (continued)

142 NICOTINE a) Maximum of 768 piece per prescription b) Maximum of 384 piece per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 384 piece per dispensing cannot be waived via Access Exemption Criteria. Gum 2 mg (Fruit) .................................................................... 23.41 96 OP ✔ Nicotinell Gum 2 mg (Mint) .................................................................... 23.41 96 OP ✔ Nicotinell Gum 4 mg (Fruit) .................................................................... 23.41 96 OP ✔ Nicotinell Gum 4 mg (Mint) .................................................................... 23.41 96 OP ✔ Nicotinell AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg ............................................................................. 18.45 (34.90) IPRATROPIUM BROMIDE Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO ................................................................................... 3.79 Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available on a PSO ................................................................................... 4.06 100 ✔ Azamun Imuran

156 163

20 20

✔ Ipratropium Steri-Neb ✔ Ipratropium Steri-Neb

186

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA0896 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.60 200 ml OP ✔ Nutrini Energy RTH Note – Nutrini Energy RTH liquid 500 ml OP remains subsidised. PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0896 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.07 200 ml OP ✔ Nutrini RTH Note – Nutrini RTH liquid 500 ml OP remains subsidised. ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.75 250 ml OP ✔ Isosource 1.5 ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.33 237 ml OP ✔ Resource Plus AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0962 – Retail pharmacy – See prescribing guideline Powder .................................................................................. 58.44 250 g OP ✔ Metabolic Mineral Mixture Note – Metabolic Mineral Mixture powder 100 g OP remains subsidised.

186

190 191 196

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 April 2011

37 VITAMINS ❋ Tab (BPC cap strength) ............................................................ 8.00 (14.80) CAPTOPRIL ❋ Tab 12.5 mg .......................................................................... 10.00 (10.40) ❋ Tab 25 mg ............................................................................. 12.00 (13.40) ❋ Tab 50 mg ............................................................................. 17.50 (19.00) PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Imuprine is 2377829 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Dapa-Tabs is 2377837 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Univent is 2377845 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Arrow Terazosin is 2377853 1,000 Healtheries Multivitamin tablets 500 Apo-Captopril 500 Apo-Captopril 500 Apo-Captopril 1 fee 1 fee 1 fee 1 fee ✔ BSF Imuprine ✔ BSF Dapa-Tabs ✔ BSF Univent ✔ BSF Arrow Terazosin

48 171 197

GOATS MILK INFANT FORMULA – Special Authority see SA0604 – Retail pharmacy Powder ..................................................................................... 9.42 900 g OP (22.75) LACTOSE FREE INFANT FORMULA – Special Authority see SA0604 – Retail pharmacy Powder ..................................................................................... 5.66 900 g OP (17.95) SOYA INFANT FORMULA – Special Authority see SA0604 – Retail pharmacy Powder ..................................................................................... 6.34 900 g OP (19.57) INFANT SOY FORMULA – Special Authority see SA0757 – Retail pharmacy Powder ..................................................................................... 7.27 (16.35) 900 g

Karicare Goats Milk Infant Formula

198

Delact

198

S26 Soy

198

Karicare Soy All Ages

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be delisted – effective 1 May 2011

87 ITRACONAZOLE – Retail pharmacy-Specialist Cap 100 mg ............................................................................. 4.25 (23.70) 15 Sporanox

127

ONDANSETRON a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 c) Not more than one prescription per month; can be waived by Special Authority see SA0887. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg ................................................................................. 1.70 10 (17.18) Zofran Tab 8 mg ................................................................................. 3.40 20 (33.89) Zofran PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee ....................................................................... 0.01 The Pharmacode for BSF Apo-Clopidogrel is 2378655 1 fee ✔ BSF Apo-Clopidogrel

171

Effective 1 June 2011

34 171 LACTULOSE – Only on a prescription ❋ Oral liq 10 g per 15 ml ............................................................... 6.65 PHARMACY SERVICES – May only be claimed once per patient ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Zapril is 2378639 1, 000 ml ✔ Duphalac 1 fee ✔ BSF Zapril

Effective 1 July 2011

64 116 118 POVIDONE IODINE Antiseptic soln 10% ................................................................ 51.06 LIGNOCAINE HYDROCHLORIDE Inj 0.5%, 5 ml – Up to 5 inj available on a PSO ......................... 44.10 MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable Cap long-acting 200 mg ......................................................... 17.00 4,500 ml 50 ✔ Betadine ✔ Xylocaine

✔ m-Eslon

Effective 1 August 2011

36 PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 25 mg – No patient co-payment payable ............................ 3.06 MEXILETINE HYDROCHLORIDE ▲ Cap 50 mg ............................................................................. 23.52 ▲ Cap 200 mg ........................................................................... 55.05 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

90 100 100

✔ Healtheries ✔ Mexitil ✔ Mexitil

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be delisted – effective 1 August 2011 (continued)

66 SUNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Crm .......................................................................................... 1.28 50 g OP (5.50) Aquasun Oil Free Faces SPF30+ STAVUDINE [D4T] – Special Authority see SA1025 – Retail pharmacy Cap 20 mg ........................................................................... 317.10 Powder for oral soln 1 mg per ml .......................................... 100.76 FENTANYL a) Only on a controlled drug form b) No patient co-payment payable Transdermal patch, matrix 25 µg per hour – Special Authority see SA1080 – Retail pharmacy ............................................ 55.23 Transdermal patch, matrix 50 µg per hour – Special Authority see SA1080 – Retail pharmacy .......................................... 100.52 Transdermal patch, matrix 75 µg per hour – Special Authority see SA1080 – Retail pharmacy .......................................... 139.18 Transdermal patch, matrix 100 µg per hour – Special Authority see SA1080 – Retail pharmacy .......................................... 171.22 MITOMYCIN C – PCT only – Specialist Inj 2 mg ............................................................................... 283.00 Inj 10 mg ............................................................................. 808.00 Note – Arrow mitomycin C inj 5 mg remains subsidised. 60 ✔ Zerit 200 ml OP ✔ Zerit

117

5 5 5 5 10 5

✔ Durogesic ✔ Durogesic ✔ Durogesic ✔ Durogesic ✔ Mitomycin-C S29 ✔ Mitomycin-C S29

149

Effective 1 September 2011

41 50 65 CLOPIDOGREL Tab 75 mg ................................................................................ 5.05 DIGOXIN ❋ Tab 62.5 µg – Up to 30 tab available on a PSO .......................... 6.94 28 250 ✔ Apo-Clopidogrel ✔ Lanoxin PG

SULPHUR Precipitated – Only in combination ............................................. 6.50 100 g ✔ ABM 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 172 2) With or without other dermatological galenicals. CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority SA0988 Tab 250 mg .............................................................................. 5.53 10 ✔ Klacid RITONAVIR – Special Authority see SA1025 – Retail pharmacy Cap 100 mg ......................................................................... 121.27 NAPROXEN SODIUM ❋ Tab 275 mg .............................................................................. 5.69 CLADRIBINE – PCT only – Specialist Inj 2 mg per ml, 5 ml ............................................................ 873.00 84 120 1 ✔ Norvir ✔ Sonaflam ✔ Litak S29

83 94 100 145

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be delisted – effective 1 September 2011 (continued)

178 178 METHYL HYDROXYBENZOATE Powder ................................................................................... 10.00 SODIUM BICARBONATE Powder BP – Only in combination .............................................. 9.80 (11.99) Only in extemporaneously compounded omeprazole suspension. 25 g 500 g ✔ ABM ✔ ABM Biomed

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 March 2011

20 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP Blood glucose test strips × 50 and lancets × 5 ..................... 19.10 19.60 BUPIVACAINE HYDROCHLORIDE ( price) Inf 0.25%, 100 ml theatre pack ............................................. 150.00 Inj 0.5%, 4 ml ......................................................................... 50.00 Inj 0.5%, 8% glucose, 4 ml ..................................................... 38.00 CEFACLOR MONOHYDRATE Cap 250 mg – 1% DV Jun-11 to 2013..................................... 24.57 Note – Ranbaxy-Cefaclor cap 250 mg to be delisted 1 June 2011. CEFTRIAXONE SODIUM Inj 1 g – 1% DV Oct-10 to 2013 .............................................. 10.49 Note – HSS suspended from 18 February 2011. CETOMACROGOL Crm BP 500 g .......................................................................... 3.50 Note - Pharmacy Health crm BP 500 g, 12 pot pack, delisted 1 March 2011. DARUNAVIR Tab 600 mg ...................................................................... 1,190.00 ISOPROPYL ALCOHOL Soln 70%, 500 ml ..................................................................... 5.00 LANSOPRAZOLE Cap 15 mg ............................................................................... 3.27 Cap 30 mg ............................................................................... 4.34 50 test 1 On Call Advanced CareSens Marcain Marcain Isobaric Marcain Heavy Cefaclor Sandoz

5 5 5 100

Aspen Ceftriaxone

Pharmacy Health

27 38 39

60 1 28 28

Prezista PSM Lanzol Relief Lanzol Relief ABM

METHYL HYDROXYBENZOATE Powder .................................................................................. 10.00 25 g Note – ABM methyl hydroxybenzoate powder, 25 g to be delisted 1 May 2011. NAPROXEN SODIUM Tab 275 mg ............................................................................. 6.00 Note – Sonaflam tab 275 mg to be delisted 1 May 2011. NEOSTIGMINE METHYLSULPHATE ( price) Inj 2.5 mg per ml, 1 ml ......................................................... 150.00 OCTREOTIDE ( price) Inj 50 µg per ml, 1 ml ............................................................. 43.50 Inj 100 µg per ml, 1 ml ........................................................... 81.00 Inj 500 µg per ml, 1 ml ......................................................... 399.00 120

Sonaflam

45 46

50 5 5 5

AstraZeneca Sandostatin Sandostatin Sandostatin

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 March 2011 (continued)

47 ONDANSETRON Tab disp 4 mg – 1% DV May-11 to 2013 ................................. 1.70 Tab disp 8 mg – 1% DV May-11 to 2013 .................................. 2.00 Note – Zofran Zydis tab disp 4 mg and 8 mg to be delisted 1 May 2011. 52 RETINOL PALMITATE Oint 25 g .................................................................................. 2.00 Note - PSM oint 25 g, 80 tube pack, delisted 1 March 2011. RITONAVIR Tab 100 mg ........................................................................... 43.31 Note - Norvir cap 100 mg to be delisted 1 May 2011. 1 PSM 10 10 Dr Reddy’s Ondansetron Dr Reddy’s Ondansetron

Norvir

SODIUM BICARBONATE Powder BP ................................................................................ 9.80 500 g ABM 11.99 Biomed Note – ABM and Biomed brands of sodium bicarbonate powder BP, 500 g to be delisted 1 May 2011. SORBOLENE WITH GLYCERIN Crm with 10% glycerine, 100 g (pot).......................................... 2.10 1 Pharmacy Health Crm with 10% glycerine, 100 g (tube) ........................................ 2.00 1 Pharmacy Health Crm with 10% glycerine, 500 ml ............................................... 4.50 1 Pharmacy Health Crm with 10% glycerine, 1,000 ml ............................................ 6.50 1 Pharmacy Health Note - Pharmacy Health crm with 10% glycerine, 100 g, 500 ml and 1,000 ml, multiple packs delisted 1 March 2011. SULPHUR Precipitated .............................................................................. 6.50 Note – ABM sulphur precipitated 100 g to be delisted 1 May 2011. 100 g ABM

VARENICLINE TARTRATE Tab 0.5 mg × 11 and 1 mg × 14 .......................................... 60.48 25 1 Champix Note – pack size change from 1 to 25 tablets. The pharmacode for this pack has also changed.

Effective 1 February 2011

21 CAFFEINE CITRATE (presentation description change and  price) Oral liq 20 mg per ml (10 mg base per ml) ............................. 14.85 Inj 20 mg per ml (10 mg base per ml), 2.5 ml ........................ 55.75 FENTANYL Transdermal patch 12.5 µg per hour – 1% DV Aug-11 to 2013 ......................................................... 8.90 Transdermal patch 25 µg per hour – 1% DV Aug-11 to 2013 ......................................................... 9.15 25 ml 5 Biomed Biomed

5 5

Mylan Fentanyl Patch Mylan Fentanyl Patch continued...

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 February 2011 (continued)

continued... Transdermal patch 50 µg per hour – 1% DV Aug-11 to 2013 ....................................................... 11.50 Transdermal patch 75 µg per hour – 1% DV Aug-11 to 2013 ....................................................... 13.60 Transdermal patch 100 µg per hour – 1% DV Aug-11 to 2013 ....................................................... 14.50 33 34 GELATIN PLASMA REPLACER Inf 4% per 500 ml bag ............................................................ 92.50 GOSERELIN ACETATE ( price) Inj 3.6 mg ............................................................................ 166.20 Inj 10.8 mg .......................................................................... 443.76 POTASSIUM CITRATE Oral liq 3 mmol per ml ............................................................ 30.00 PROPOFOL ( price) Inj 1%, 20 ml .......................................................................... 42.00 Inj 1%, 50 ml .......................................................................... 25.00 Inj 1%, 50 ml prefilled syringe ................................................. 47.00 Inj 1%, 100 ml ........................................................................ 30.00 Inj 2%, 50 ml prefilled syringe ................................................. 60.00 RISPERIDONE (presentation description change only) Inj Microspheres for inj 25 mg per 2 ml ................................ 175.00 Inj Microspheres for inj 37.5 mg per 2 ml ............................. 230.00 Inj Microspheres for inj 50 mg per 2 ml ................................ 280.00 ROPIVACAINE HYDROCHLORIDE ( price) Inj 2 mg per ml, 20 ml ............................................................ 75.00 Inf 2 mg per ml, 100 ml ........................................................ 200.00 Inf 2 mg per ml, 200 ml ........................................................ 265.00 Inj 7.5 mg per ml, 10 ml ......................................................... 45.00 Inj 7.5 mg per ml, 20 ml ......................................................... 84.00 Inj 10 mg per ml, 10 ml .......................................................... 54.00 SODIUM CHLORIDE Soln 7% ................................................................................. 23.50 SUXAMETHONIUM CHLORIDE ( price) Inj 50 mg per ml, 2 ml .......................................................... 130.00 TRIAMCINOLONE ACETONIDE ( price) Inj 40 mg per ml, 1 ml – 1% DV Dec-08 to 2011 ..................... 28.09 5 5 5 Mylan Fentanyl Patch Mylan Fentanyl Patch Mylan Fentanyl Patch Gelafusal Zoladex Zoladex Biomed Diprivan Diprivan Diprivan Diprivan Diprivan Risperdal Consta Risperdal Consta Risperdal Consta Naropin Naropin Naropin Naropin Naropin Naropin Biomed AstraZeneca Kenacort-A40

10 1 1 200 ml 5 1 1 1 1 1 1 1 5 5 5 5 5 5 90 ml 50 5

49 51

55 58 60

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 January 2010

20 BUPIVACAINE HYDROCHLORIDE Inf 0.125%, 100 ml theatre pack ........................................... 109.39 5 Marcain Inf 0.125%, 200 ml theatre pack ........................................... 146.23 5 Marcain Inj 0.375%, 20 ml theatre pack ............................................... 56.20 5 Marcain Note – Marcain inf 0.125%, 100 ml and 200 ml theatre packs, and inj 0.375%, 20 ml theatre pack, delisted 1 January 2011 LACTULOSE Oral liq 10 g per 15 ml – 1% DV Mar-11 to 2013....................... 7.68 Note – Duphalac oral liq 10 g per 15 ml to be delisted 1 March 2011 LIGNOCAINE HYDROCHLORIDE Inj 0.5%, 5 ml ......................................................................... 44.10 Note – Xylocaine inj 0.5%, 5 ml delisted 1 January 2011 MORPHINE SULPHATE Cap long-acting 200 mg .......................................................... 17.00 Note: m-Eslon cap long-acting 200 mg to be delisted 1 March 2011 NICOTINE (new listings) Gum 2 mg (classic)................................................................. 14.97 Gum 4 mg (classic)................................................................. 20.02 NICOTINE (expiry of HSS) Note: Nicotrol and Nicorette patches are DV Pharmaceuticals. Patch 7 mg – 10% DV Apr-08 to 31 Dec 2010 ........................ 10.53 Patch 14 mg – 10% DV Apr-08 to 31 Dec 2010 ...................... 11.63 Patch 21 mg – 10% DV Apr-08 to 31 Dec 2010 ...................... 12.32 Lozenge 1 mg – 10% DV Apr-08 to 31 Dec 2010 .................... 11.08 Lozenge 2 mg – 10% DV Apr-08 to 31 Dec 2010 .................... 11.08 Gum 2 mg (fruit) – 10% DV Apr-08 to 31 Dec 2010 ................. 14.97 Gum 2 mg (mint) – 10% DV Apr-08 to 31 Dec 2010 ............... 14.97 Gum 4 mg (fruit) – 10% DV Apr-08 to 31 Dec 2010 ................. 20.02 Gum 4 mg (mint) – 10% DV Apr-08 to 31 Dec 2010 ............... 20.02 RALTEGRAVIR POTASSIUM ( price) Tab 400 mg ...................................................................... 1,090.00 ROCURONIUM BROMIDE Inj 10 mg per ml, 5 ml - 1% DV Mar-11 to 2012...................... 85.00 1,000 ml Laevolac

Xylocaine

m-Eslon

96 96

Habitrol Habitrol

7 7 7 36 36 96 96 96 96 60 10

Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Isentress Arrow-Rocuronium

51 53 54

ROPIVACAINE HYDROCHLORIDE Inj 2 mg per ml, 10 ml ............................................................ 19.75 5 Naropin Inj 10 mg per ml, 20 ml .......................................................... 74.20 5 Naropin Note – Naropin inj 2 mg per ml, 10 ml, and inj 10 mg per ml, 20 ml, delisted 1 January 2011 SODIUM CHLORIDE Inj 0.9%, 5 ml ......................................................................... 10.85 Inj 0.9%, 10 ml ....................................................................... 11.50 50 50 Multichem Multichem

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 January 2011 (continued)

62 ZINC AND CASTOR OIL ( price) Ointment .................................................................................. 1.29 20 g Orion

Effective 1 December 2010

21 CALCIUM FOLINATE (extension of HSS) Inj 50 mg – 1% DV Sep-08 to 2014 ....................................... 24.50 Inj 100 mg – 1% DV Sep-08 to 2014 ....................................... 9.75 Inj 300 mg – 1% DV Sep-08 to 2014 ..................................... 30.00 Inj 1 g – 1% DV Sep-08 to 2014 ( price)................................ 90.00 22 CARBOPLATIN ( price) Inj 10 mg per ml, 45 ml – 1% DV Dec-09 to 2012 ................... 50.00 Inj 10 mg per ml, 100 ml – 1% DV Dec-09 to 2012 ............... 105.00 5 1 1 1 Calcium Folinate Ebewe Calcium Folinate Ebewe Calcium Folinate Ebewe Calcium Folinate Ebewe Carboplatin Ebewe Carboplatin Ebewe

1 1

DOPAMINE HYDROCHLORIDE Inj 40 mg per ml, 5 ml – 1% DV Feb-11 to 2012 ..................... 82.08 10 Max Health Note – Mayne’s brand of dopamine hydrochloride inj 40 mg per ml, 5 ml to be delisted 1 February 2011. DOXORUBICIN (addition of HSS) Inj 10 mg – 1% DV Feb-11 to 2012 ( price) ........................... 10.00 Inj 50 mg – 1% DV Feb-11 to 2012 ( price) ........................... 40.00 Inj 100 mg – 1% DV Feb-11 to 2012 ( price) ......................... 80.00 Inj 200 mg – 1% DV Feb-11 to 2012 ( price) ....................... 150.00 EPIRUBICIN ( price) Inj 2 mg per ml, 50 ml – 1% DV Oct-09 to 2012 .................... 125.00 Inj 2 mg per ml, 100 ml – 1% DV Oct-09 to 2012 .................. 210.00 ESCITALOPRAM Tab 10 mg – 1% DV Feb-11 to 2013 ......................................... 2.65 Tab 20 mg – 1% DV Feb-11 to 2013 ......................................... 4.20 GEMFIBROZIL Tab 600 mg – 1% DV Feb-11 to 2013 ..................................... 14.00 GLYCERIN WITH SUCROSE Suspension ............................................................................. 38.00 GLYCERIN WITH SODIUM SACCHARIN Suspension ............................................................................. 38.00 ITRACONAZOLE Cap 100 mg – 1% DV Feb-11 to 2013 ...................................... 4.25 Note – Sporanox cap 100 mg to be delisted 1 February 2011. 1 1 1 1 1 1 28 28 60 473 ml 473 ml 15 Doxorubicin Ebewe Doxorubicin Ebewe Doxorubicin Ebewe Doxorubicin Ebewe Epirubicin Ebewe Epirubicin Ebewe Loxalate Loxalate Lipazil Ora-Sweet Ora-Sweet SF Itrazole

33 34 34 38

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 December 2010 (continued)

38 39 ISOSORBIDE MONONITRATE ( price) Tab long-acting 60 mg ............................................................. 3.94 LABETALOL ( price) Tab 50 mg ............................................................................... 8.23 Tab 100 mg ........................................................................... 10.06 Tab 200 mg ........................................................................... 17.55 LABETALOL Tab 400 mg ........................................................................... 34.44 Note – Hybloc tab 400 mg to be delisted 1 February 2011. METHOTREXATE ( price and extension of HSS) Inj 100 mg per ml, 10 ml – 1% DV Nov-08 to 2014 ................. 25.00 Inj 100 mg per ml, 50 ml – 1% DV Nov-08 to 2014 ............... 125.00 METHYLCELLULOSE Suspension ............................................................................. 38.00 METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension ............................................................................. 38.00 METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension ............................................................................. 38.00 MOXIFLOXACIN Tab 400 mg ............................................................................ 52.00 Soln for inf 1.6 mg per ml, 250 ml ........................................... 70.00 NIFEDIPINE ( price) Tab long-acting 30 mg ............................................................. 8.56 Tab long-acting 60 mg ........................................................... 12.28 OXALIPLATIN ( price) Inj 50 mg – 1% DV Jan-10 to 2012 ......................................... 55.00 Inj 100 mg – 1% DV Jan-10 to 2012 ..................................... 110.00 PACLITAXEL ( price and extension of HSS) Inj 30 mg – 1% DV Oct-08 to 2014 ...................................... 137.50 Inj 100 mg – 1% DV Oct-08 to 2014 ....................................... 91.67 Inj 150 mg – 1% DV Oct-08 to 2014 ..................................... 137.50 Inj 300 mg – 1% DV Oct-08 to 2014 ..................................... 275.00 Inj 600 mg – 1% DV Oct-08 to 2014 ..................................... 550.00 PROPRANOLOL ( price) Cap long-acting 160 mg ......................................................... 16.06 RIVAROXABAN Tab 10 mg ............................................................................ 153.00 306.00 90 100 100 100 100 Duride Hybloc Hybloc Hybloc Hybloc

1 1 473 ml 473 ml 473 ml 5 1 30 30 1 1 5 1 1 1 1 100 15 30

Methotrexate Ebewe Methotrexate Ebewe Ora-Plus Ora-Blend Ora-Blend SF Avelox Avelox IV 400 Adefin XL Adefin XL Oxaliplatin Ebewe Oxaliplatin Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Cardinol LA Xarelto Xarelto

43 43 43 45

51 53

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 December 2010 (continued)

54 SERTRALINE Tab 50 mg – 1% DV Feb-11 to 2013......................................... 5.40 Tab 100 mg – 1% DV Feb-11 to 2013 ....................................... 9.60 SODIUM CHLORIDE Inf 0.9% ................................................................................... 1.70 1.71 VERAPAMIL HYDROCHLORIDE Tab long-acting 120 mg ......................................................... 15.20 90 90 500 ml 1,000 ml 250 Arrow-Sertraline Arrow-Sertraline Freeflex Freeflex Verpamil SR

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands A Adefin XL ........................................................... 53 Aminoacid formula with minerals without phenylalanine .................................................. 43 Amoxycillin ........................................................ 39 Anusol ............................................................... 40 Apo-Amoxi......................................................... 39 Apo-Ascorbic Acid ............................................. 41 Apo-B-Complex ................................................. 39 Apo-Bromocriptine ............................................. 28 Apo-Captopril ............................................... 37, 44 Apo-Clopidogrel ........................................... 26, 46 Apo-Terazosin.................................................... 41 Applicator .......................................................... 42 Aquasun Oil Free Faces SPF30+ ........................ 46 Arrow-Clopidogrel .............................................. 39 Arrow-Rocuronium ............................................ 51 Arrow-Sertraline ................................................. 54 Ascorbic acid ..................................................... 41 Aspen Ceftriaxone .............................................. 48 Avelox.......................................................... 28, 53 Avelox IV 400..................................................... 53 Azamun ............................................................. 43 Azathioprine ................................................. 34, 43 B Batrafen ............................................................. 41 Betadine............................................................. 45 Blood glucose diagnostic test strip ............... 24, 48 Bromocriptine mesylate...................................... 28 Brufen SR .......................................................... 38 BSF Apo-Clopidogrel .................................... 21, 45 BSF Arrow-Enalapril ........................................... 40 BSF Arrow Terazosin .................................... 23, 44 BSF Dapa-Tabs ............................................ 23, 44 BSF Imuprine ............................................... 23, 44 BSF Univent ................................................. 23, 44 BSF Zapril .................................................... 20, 45 Bupivacaine hydrochloride............................ 48, 51 C Caffeine citrate ............................................. 21, 49 Calcium folinate ................................................. 52 Calcium Folinate Ebewe...................................... 52 Captopril ...................................................... 37, 44 Carboplatin ........................................................ 52 Carboplatin Ebewe ............................................. 52 Cardinol LA ........................................................ 53 CareSens ..................................................... 24, 48 Cefaclor monohydrate .................................. 20, 48 Cefaclor Sandoz ........................................... 20, 48 Ceftriaxone sodium ................................ 40, 42, 48 Cerezyme........................................................... 24 Cetomacrogol .................................................... 48 Champix ...................................................... 25, 49 Chloramphenicol ................................................ 39 Chlorsig ............................................................. 39 Ciclopiroxolamine............................................... 41 Cilazapril ...................................................... 24, 39 Cladribine........................................................... 46 Clarithromycin.............................................. 20, 46 Clomiphene citrate ............................................. 40 Clopidogrel ............................................ 26, 39, 46 Cromolux ........................................................... 40 Cyclizine lactate ................................................. 39 D Dapa-Tabs ......................................................... 28 Dapsone ............................................................ 28 Darunavir ..................................................... 20, 48 Delact ................................................................ 44 Derbac-M .......................................................... 42 Dexamphetamine sulphate.................................. 31 Diaphragm ......................................................... 42 Digoxin ........................................................ 20, 46 Diphemanil methylsulphate ................................. 41 Diprivan ............................................................. 50 Dopamine hydrochloride .................................... 52 Doxorubicin ....................................................... 52 Doxorubicin Ebewe ............................................ 52 Dr Reddy’s Ondansetron .............................. 20, 49 Duolin HFA ......................................................... 21 Duphalac ..................................................... 36, 45 Duride ................................................................ 53 Durogesic .............................................. 26, 27, 46 E Enteral feed with fibre 1.5kcal/ml ........................ 43 Epirubicin........................................................... 52 Epirubicin Ebewe................................................ 52 Escitalopram ...................................................... 52 Estradot ............................................................. 21 Extemporaneously compounded products & galenicals...................................... 34 Ezetimibe ........................................................... 36 Ezetimibe with simvastatin ................................. 36 Ezetrol ............................................................... 36 F Fentanyl ........................................... 21, 26, 46, 49 Fluarix .......................................................... 22, 25 Fluvax .................................................... 22, 25, 42 Freeflex .............................................................. 54 Furosemide ........................................................ 40 G Gabapentin ........................................................ 28 Gaviscon ........................................................... 40 Gelafusal............................................................ 50 Gelatin plasma replacer ...................................... 50

Index

Pharmaceuticals and brands Gemcitabine Ebewe............................................ 25 Gemcitabine hydrochloride ................................. 25 Gemfibrozil ........................................................ 52 Gemzar .............................................................. 25 Glycerin with sodium saccharin .......................... 52 Glycerin with sucrose ......................................... 52 Glycerol with paraffin and cetyl alcohol ............... 41 Goats milk infant formula.................................... 44 Goserelin acetate ......................................... 36, 50 Gynol II .............................................................. 42 H Habitrol ............................................ 22, 33, 34, 51 Healtheries Multi-vitamin tablets ................... 37, 44 Hyalase.............................................................. 36 Hyaluronidase .................................................... 36 Hybloc ............................................................... 53 Hydrocortisone butyrate with chlorquinaldol........ 39 Hydrogen peroxide ............................................. 42 Hytrin Starter Pack ............................................. 41 I Ibuprofen ........................................................... 38 Imiglucerase ...................................................... 24 Imuprine ............................................................ 34 Imuran ............................................................... 43 Indapamide .................................................. 28, 41 Indomethacin ..................................................... 40 Infant soy formula .............................................. 44 Influenza vaccine.................................... 22, 24, 42 Influvac .............................................................. 42 Inhibace ............................................................. 39 Ipratropium bromide ..................................... 34, 43 Ipratropium Steri-Neb ......................................... 43 Isentress ...................................................... 37, 51 Isogel................................................................. 39 Isopropyl alcohol................................................ 48 Isosorbide mononitrate....................................... 53 Isosource 1.5..................................................... 43 Itraconazole ........................................... 36, 45, 52 Itrazole ............................................................... 52 J Janola ................................................................ 41 K Karicare Goats Milk Infant Formula ..................... 44 Karicare Soy All Ages ......................................... 44 Kenacort-A40..................................................... 50 Klacid .......................................................... 20, 46 Konsyl-D............................................................ 39 L Labetalol ............................................................ 53 Lactose free infant formula ................................. 44 Lactulose ......................................... 21, 36, 45, 51 Laevolac ...................................................... 21, 51 Lanoxin PG .................................................. 20, 46 Lansoprazole ............................................... 20, 48 Lanzol Relief ................................................ 20, 48 Lignocaine hydrochloride ............................. 45, 51 Lincocin ............................................................. 21 Lincomycin ........................................................ 21 Lipazil ................................................................ 52 Litak .................................................................. 46 Lithium carbonate .............................................. 36 Locoid C ............................................................ 39 Loxalate ............................................................. 52 M m-Eslon ....................................................... 45, 51 Malathion ........................................................... 42 Marcain ....................................................... 48, 51 Marcain Heavy ................................................... 48 Marcain Isobaric ................................................ 48 Metabolic Mineral Mixture................................... 43 Metamucil .......................................................... 39 Methotrexate ................................................ 37, 53 Methotrexate Ebewe ........................................... 53 Methylcellulose .................................................. 53 Methylcellulose with glycerin and sodium saccharin ........................................................ 53 Methylcellulose with glycerin and sucrose .......... 53 Methylergometrine ............................................. 39 Methyl hydroxybenzoate ............................... 47, 48 Methylphenidate hydrochloride ........................... 32 Mexiletine hydrochloride ..................................... 45 Mexitil ................................................................ 45 Microlax ............................................................. 40 Mitomycin C ................................................ 34, 46 Mitomycin-C ...................................................... 46 Morphine sulphate........................................ 45, 51 Moxifloxacin................................................. 28, 53 Mucilaginous laxatives ....................................... 39 Mucilax .............................................................. 39 Multivitamins ..................................................... 41 Mylan Fentanyl Patch ............................. 21, 49, 50 N Napamide .......................................................... 41 Naproxen sodium ......................................... 46, 48 Naropin ........................................................ 50, 51 Neostigmine....................................................... 36 Neostigmine methylsulphate ............................... 48 Nicotine ..................................... 22, 33, 34, 43, 51 Nicotinell ............................................................ 43 Nifedipine........................................................... 53 Nonoxynol-9 ...................................................... 42 Normacol ........................................................... 39 Norvir .................................................... 20, 46, 49 Nupentin ............................................................ 28

Index

Pharmaceuticals and brands Nutrini Energy RTH ............................................. 43 Nutrini RTH ........................................................ 43 O Octreotide .......................................................... 48 Oestradiol .......................................................... 21 Oily cream ......................................................... 41 On Call Advanced ......................................... 24, 48 Ondansetron .................................... 20, 36, 45, 49 Ora-Blend .......................................................... 53 Ora-Blend SF...................................................... 53 Oral feed 1.5kcal/ml ..................................... 40, 43 Oral feed 1kcal/ml .............................................. 40 Ora-Plus ............................................................ 53 Ora-Sweet.......................................................... 52 Ora-Sweet SF ..................................................... 52 Ortho ................................................................. 42 Ortho All-flex ...................................................... 42 Ortho Coil .......................................................... 42 Oxaliplatin Ebewe ............................................... 53 Oxaliplatin .......................................................... 53 P Paclitaxel ........................................................... 53 Paclitaxel Ebewe ................................................ 53 Paediatric enteral feed 1.5kcal/ml ....................... 43 Paediatric enteral feed 1kcal/ml .......................... 43 Paediatric Seravit ............................................... 41 Pharmacy services............... 20, 21, 23, 40, 44, 45 Phenate ............................................................. 40 Plavix ................................................................. 39 Polytar Emollient ................................................ 42 Potassium chloride ............................................ 36 Potassium citrate ......................................... 20, 50 Povidone iodine ................................................. 45 Prantal ............................................................... 41 Prezista........................................................ 20, 48 Priadel ............................................................... 36 Propofol ............................................................. 50 Propranolol ........................................................ 53 Pyridoxine hydrochloride .................................... 45 Q QV ..................................................................... 41 R Raltegravir potassium................................... 37, 51 Resource Diabetic .............................................. 40 Resource Plus.............................................. 40, 43 Retinol palmitate ................................................ 49 Rheumacin SR ................................................... 40 Risperdal Consta .......................................... 27, 50 Risperidone.................................................. 27, 50 Ritalin ................................................................ 32 Ritalin SR ........................................................... 32 Ritonavir ................................................ 20, 46, 49 Rivaroxaban ....................................................... 53 Rocuronium bromide ......................................... 51 Ropivacaine hydrochloride ........................... 50, 51 Rubifen .............................................................. 32 Rubifen SR ........................................................ 32 S S26 Soy............................................................. 44 Sabril ................................................................. 30 Salbutamol with ipratropium bromide.................. 21 Sandostatin ........................................................ 48 Sertraline ........................................................... 54 Sildenafil ............................................................ 24 Sodium alginate ................................................. 40 Sodium bicarbonate ..................................... 47, 49 Sodium chloride ............................... 21, 50, 51, 54 Sodium citrate with sodium lauryl sulphoacetate.................................................. 40 Sodium cromoglycate ........................................ 40 Sodium hypochlorite .......................................... 41 Sonaflam ..................................................... 46, 48 Sorbolene with glycerin ...................................... 49 Soya infant formula ............................................ 44 Sporanox ..................................................... 36, 45 Stavudine [d4t] .................................................. 46 Sulphur ........................................................ 46, 49 Sunscreens, proprietary ..................................... 46 Suxamethonium chloride .................................... 50 T Tar with cade oil................................................. 42 Terazosin hydrochloride ............................... 28, 41 Tretinoin ............................................................ 34 Triamcinolone acetonide .................................... 50 U Univent .............................................................. 34 V Valoid (AFT) ....................................................... 39 Varenicline tartrate ....................................... 25, 49 Vaxigrip ............................................................. 42 Verapamil hydrochloride ..................................... 54 Verpamil SR ....................................................... 54 Vesanoid............................................................ 34 Viagra ................................................................ 24 Vigabatrin .......................................................... 30 Vitamin B complex ............................................. 39 Vitamins ...................................................... 37, 44 Vytorin ............................................................... 36 X Xarelto ............................................................... 53 Xylocaine ..................................................... 45, 51 Z Zapril ................................................................. 24 Zerit ................................................................... 46

Index

Pharmaceuticals and brands Zinc ................................................................... 41 Zinc and castor oil .............................................. 52 Zinc oxide .......................................................... 40 Zofran .......................................................... 36, 45 Zoladex ........................................................ 36, 50

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 March 2011

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 March 2011 Cumulative for January, February and March 2011 Section H cumulative for December 2010, January, February and March 2011 Contents Summary of PHARMAC decisions effective 1 March 2011 …..…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.